{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T18:38:42Z","timestamp":1760985522879},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Eisai Limited, Hatfield, UK"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.ejca.2016.12.018","type":"journal-article","created":{"date-parts":[[2017,2,16]],"date-time":"2017-02-16T10:35:34Z","timestamp":1487241334000},"page":"33-40","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial"],"prefix":"10.1016","volume":"75","author":[{"given":"Erik A.C.","family":"Wiemer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Wozniak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herman","family":"Burger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel","family":"Smid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Floris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axelle","family":"Nzokirantevye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raf","family":"Sciot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Sleijfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Sch\u00f6ffski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2016.12.018_bib1","series-title":"Discovery of E7389, a fully synthetic macrocyclic ketone analogue of halichondrin B","author":"Yu","year":"2005"},{"issue":"11","key":"10.1016\/j.ejca.2016.12.018_bib2","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1158\/1078-0432.CCR-14-3252","article-title":"Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent","volume":"21","author":"Dybdal-Hargreaves","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"24","key":"10.1016\/j.ejca.2016.12.018_bib3","doi-asserted-by":"crossref","first-page":"15882","DOI":"10.1016\/S0021-9258(18)98491-7","article-title":"Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data","volume":"266","author":"Bai","year":"1991","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.ejca.2016.12.018_bib4","first-page":"1013","article-title":"In\u00a0vitro and in\u00a0vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B","volume":"61","author":"Towle","year":"2001","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.ejca.2016.12.018_bib5","first-page":"1611","article-title":"Broad spectrum preclinical antitumor activity of eribulin (Halaven(R)): optimal effectiveness under intermittent dosing conditions","volume":"32","author":"Towle","year":"2012","journal-title":"Anticancer Res"},{"issue":"8","key":"10.1016\/j.ejca.2016.12.018_bib6","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1002\/pbc.24517","article-title":"Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program","volume":"60","author":"Kolb","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"16","key":"10.1016\/j.ejca.2016.12.018_bib7","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1158\/0008-5472.CAN-04-1169","article-title":"Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389","volume":"64","author":"Kuznetsov","year":"2004","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.ejca.2016.12.018_bib8","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1158\/0008-5472.CAN-10-1874","article-title":"Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in\u00a0vivo efficacy under intermittent dosing conditions","volume":"71","author":"Towle","year":"2011","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.ejca.2016.12.018_bib9","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1021\/bi901810u","article-title":"Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability","volume":"49","author":"Smith","year":"2010","journal-title":"Biochemistry"},{"issue":"7","key":"10.1016\/j.ejca.2016.12.018_bib10","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1158\/1535-7163.MCT-04-0345","article-title":"The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth","volume":"4","author":"Jordan","year":"2005","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"10.1016\/j.ejca.2016.12.018_bib11","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1038\/bjc.2014.80","article-title":"Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states","volume":"110","author":"Yoshida","year":"2014","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2016.12.018_bib12","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.ajpath.2014.10.006","article-title":"Characterization of a new small bowel adenocarcinoma cell line and screening of anti-cancer drug against small bowel adenocarcinoma","volume":"185","author":"Suzuki","year":"2015","journal-title":"Am J Pathol"},{"issue":"10","key":"10.1016\/j.ejca.2016.12.018_bib13","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1111\/cas.12488","article-title":"Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models","volume":"105","author":"Funahashi","year":"2014","journal-title":"Cancer Sci"},{"issue":"8","key":"10.1016\/j.ejca.2016.12.018_bib14","doi-asserted-by":"crossref","first-page":"5016","DOI":"10.3390\/md13085016","article-title":"Eribulin in cancer treatment","volume":"13","author":"Swami","year":"2015","journal-title":"Mar Drugs"},{"issue":"9769","key":"10.1016\/j.ejca.2016.12.018_bib15","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","article-title":"Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study","volume":"377","author":"Cortes","year":"2011","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ejca.2016.12.018_bib16","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1470-2045(11)70230-3","article-title":"Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes","volume":"12","author":"Sch\u00f6ffski","year":"2011","journal-title":"Lancet Oncol"},{"issue":"10028","key":"10.1016\/j.ejca.2016.12.018_bib17","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/S0140-6736(15)01283-0","article-title":"Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial","volume":"387","author":"Sch\u00f6ffski","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ejca.2016.12.018_bib18","doi-asserted-by":"crossref","first-page":"908","DOI":"10.2353\/ajpath.2010.091150","article-title":"A differentiation-based microRNA signature identifies leiomyosarcoma as a mesenchymal stem cell-related malignancy","volume":"177","author":"Danielson","year":"2010","journal-title":"Am J Pathol"},{"issue":"2","key":"10.1016\/j.ejca.2016.12.018_bib19","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/ijc.28694","article-title":"MicroRNA expression profiles distinguish liposarcoma subtypes and implicate miR-145 and miR-451 as tumor suppressors","volume":"135","author":"Gits","year":"2014","journal-title":"Int J Cancer"},{"issue":"14","key":"10.1016\/j.ejca.2016.12.018_bib20","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1038\/sj.onc.1210836","article-title":"MicroRNA expression signature of human sarcomas","volume":"27","author":"Subramanian","year":"2008","journal-title":"Oncogene"},{"issue":"17","key":"10.1016\/j.ejca.2016.12.018_bib21","doi-asserted-by":"crossref","first-page":"5659","DOI":"10.1158\/0008-5472.CAN-11-0890","article-title":"Small RNA sequencing and functional characterization reveals MicroRNA-143 tumor suppressor activity in liposarcoma","volume":"71","author":"Ugras","year":"2011","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.ejca.2016.12.018_bib22","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/PPO.0b013e318258b60a","article-title":"The microRNA-17-92 family of microRNA clusters in development and disease","volume":"18","author":"Concepcion","year":"2012","journal-title":"Cancer J"},{"issue":"2","key":"10.1016\/j.ejca.2016.12.018_bib23","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cell.2008.04.001","article-title":"miRiad roles for the miR-17-92 cluster in development and disease","volume":"133","author":"Mendell","year":"2008","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.ejca.2016.12.018_bib24","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.cell.2008.02.019","article-title":"Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters","volume":"132","author":"Ventura","year":"2008","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.ejca.2016.12.018_bib25","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1073\/pnas.0510565103","article-title":"A microRNA expression signature of human solid tumors defines cancer gene targets","volume":"103","author":"Volinia","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"20","key":"10.1016\/j.ejca.2016.12.018_bib26","doi-asserted-by":"crossref","first-page":"5962","DOI":"10.3748\/wjg.v20.i20.5962","article-title":"miR-106b-25\/miR-17-92 clusters: polycistrons with oncogenic roles in hepatocellular carcinoma","volume":"20","author":"Tan","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"5","key":"10.1016\/j.ejca.2016.12.018_bib27","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.molcel.2007.05.010","article-title":"Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis","volume":"26","author":"Chang","year":"2007","journal-title":"Mol Cell"},{"issue":"5","key":"10.1016\/j.ejca.2016.12.018_bib28","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.molcel.2007.05.017","article-title":"Transcriptional activation of miR-34a contributes to p53-mediated apoptosis","volume":"26","author":"Raver-Shapira","year":"2007","journal-title":"Mol Cell"},{"key":"10.1016\/j.ejca.2016.12.018_bib29","first-page":"1","article-title":"The tumor-suppressive and potential therapeutic functions of miR-34a in epithelial carcinomas","author":"Adams","year":"2015","journal-title":"Expert Opin Ther Targets"},{"issue":"4","key":"10.1016\/j.ejca.2016.12.018_bib30","doi-asserted-by":"crossref","first-page":"872","DOI":"10.18632\/oncotarget.1825","article-title":"miR-34: from bench to bedside","volume":"5","author":"Agostini","year":"2014","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.ejca.2016.12.018_bib31","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/cas.12656","article-title":"MicroRNA-34a suppresses the breast cancer stem cell-like characteristics by downregulating Notch1 pathway","volume":"106","author":"Kang","year":"2015","journal-title":"Cancer Sci"},{"issue":"2","key":"10.1016\/j.ejca.2016.12.018_bib32","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s10549-011-1424-3","article-title":"miRNA-34a is associated with docetaxel resistance in human breast cancer cells","volume":"131","author":"Kastl","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"10.1016\/j.ejca.2016.12.018_bib33","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/path.3007","article-title":"miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy","volume":"226","author":"Nakatani","year":"2012","journal-title":"J Pathol"},{"issue":"3","key":"10.1016\/j.ejca.2016.12.018_bib34","doi-asserted-by":"crossref","first-page":"e33778","DOI":"10.1371\/journal.pone.0033778","article-title":"MicroRNA-34a inhibits the proliferation and metastasis of osteosarcoma cells both in\u00a0vitro and in\u00a0vivo","volume":"7","author":"Yan","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.ejca.2016.12.018_bib35","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00428-010-1030-5","article-title":"Frequent concomitant inactivation of miR-34a and miR-34b\/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas","volume":"458","author":"Vogt","year":"2011","journal-title":"Virchows Arch"},{"issue":"2","key":"10.1016\/j.ejca.2016.12.018_bib36","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ctrv.2012.07.005","article-title":"MicroRNAs: novel mediators of resistance to microtubule-targeting agents","volume":"39","author":"Kanakkanthara","year":"2013","journal-title":"Cancer Treat Rev"},{"issue":"14","key":"10.1016\/j.ejca.2016.12.018_bib37","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1002\/pros.21185","article-title":"MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms","volume":"70","author":"Kojima","year":"2010","journal-title":"Prostate"},{"issue":"9","key":"10.1016\/j.ejca.2016.12.018_bib38","first-page":"11524","article-title":"Deep sequencing identifies deregulation of microRNAs involved with vincristine drug-resistance of colon cancer cells","volume":"8","author":"Dong","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"issue":"2","key":"10.1016\/j.ejca.2016.12.018_bib39","doi-asserted-by":"crossref","first-page":"e0115538","DOI":"10.1371\/journal.pone.0115538","article-title":"Development and blind clinical validation of a microRNA based predictor of response to treatment with R-CHO(E)P in DLBCL","volume":"10","author":"Knudsen","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ejca.2016.12.018_bib40","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.gene.2014.11.046","article-title":"MicroRNA expression profiling and bioinformatics analysis of dysregulated microRNAs in vinorelbine-resistant breast cancer cells","volume":"556","author":"Zhong","year":"2015","journal-title":"Gene"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917300229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917300229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,24]],"date-time":"2022-07-24T04:29:48Z","timestamp":1658636988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804917300229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":40,"alternative-id":["S0959804917300229"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2016.12.018","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2016.12.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}